Snus vs Zyn: Differences, Strength and Risks (2026)

If you are comparing snus vs Zyn, the one-line answer is that snus is moist smokeless tobacco and Zyn is a nicotine pouch made of synthetic fiber, but both put nicotine into your bloodstream through your gum and both can keep you dependent. This guide sets out what the FDA and the National Cancer Institute actually say about each, how the law treats them in the US and the EU, and what to do if you are using either and want out. We could not verify everything, so the end of each section says what we could not check. For the broader snus background, see what snus is and how it compares with smoking.

The one-line difference

Snus is a type of moist snuff, which is tobacco that is not burned. The National Cancer Institute describes snuff as “finely cut or powdered tobacco,” and notes that “another name for moist snuff is snus (pronounced ‘snoose’)” (NCI fact sheet on smokeless tobacco).

Zyn is a different kind of product. The FDA describes nicotine pouches as “small synthetic fiber pouches containing nicotine designed to be placed between a person’s gum and lip” (FDA press announcement, January 16, 2025). That is the core of the difference: a pinch or pouch of tobacco held in your mouth versus a synthetic-fiber pouch of nicotine held in your mouth. We did not find the FDA describing where Zyn’s nicotine comes from, so we do not say whether it is tobacco-derived.

Both still count as tobacco products in US law, because the FDA regulates products that contain nicotine from any source. Both are used the same way, in the same place, for the same reason, which is why the habit looks so similar from the outside. For a deeper look at the pouch category itself, see our comparison of Zyn vs Velo vs on! pouches.

What is in each pouch

The NCI says the most harmful chemicals in smokeless tobacco are “tobacco-specific nitrosamines, which are formed during the growing, curing, fermenting, and aging of tobacco.” It adds that “at least 28 chemicals in smokeless tobacco have been found to cause cancer” and that “the nitrosamine level is directly related to the risk of cancer.” The level varies by product, so one snus is not identical to another (NCI).

The FDA’s reasoning about Zyn is built on that difference. It said the authorized pouches contain “substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products, such as moist snuff and snus,” and so “pose lower risk of cancer and other serious health conditions than such products” (FDA, January 2025).

What we did not fetch: a full ingredient list for any snus brand or for Zyn from the manufacturer. If a precise list matters to you, read the can and the manufacturer’s page rather than relying on a summary.

Nicotine strength compared

This is the comparison people most want and the one that is hardest to make fairly, because the two products are measured differently.

The NCI figure is per gram of tobacco, while Zyn’s figure is per pouch, so you cannot read one against the other. A pouch holds a fraction of a gram. We did not find a source that converts snus into milligrams per pouch, so we will not do the arithmetic for you.

What matters more is how much nicotine reaches your blood. The NCI says “users of smokeless tobacco and users of cigarettes have comparable levels of nicotine in the blood,” and that “the nicotine stays in the blood longer for users of smokeless tobacco than for smokers.” We found no equivalent statement for Zyn, so we cannot say how it compares.

Health evidence: what is known and what is not

Be careful with this section, because the regulators are saying two different things about two different products.

Snus and other smokeless tobacco

The NCI states that “smokeless tobacco causes oral cancer, esophageal cancer, and pancreatic cancer” and that it “may also cause heart disease, gum disease, and oral lesions other than cancer.” It also states that “there is no scientific evidence that using smokeless tobacco can help a person quit smoking” (NCI).

The FDA’s own list of modified risk orders also includes smokeless tobacco. Swedish Match’s General-brand loose and portion products first received orders on October 22, 2019, with renewals granted on November 7, 2024, according to the agency’s table, which was current as of July 15, 2026 (FDA modified risk granted orders). We did not open the wording of the General claim, so we do not quote it, and the table does not label those products as snus. Swedish snus is the product most often studied, and we did not fetch a Swedish study, so we will not generalize those results to American dip or to any other brand.

Zyn

Zyn has two separate FDA decisions, and they are not the same thing. On January 16, 2025, the FDA authorized 20 Zyn products through the premarket (PMTA) pathway, “the first time the agency has authorized products commonly referred to as nicotine pouches.” That authorization let the products be sold; the same release said it did not allow the company to make reduced risk claims. On June 30, 2026, the FDA went further and issued modified risk (MRTP) granted orders for those 20 products, allowing this claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” The FDA said the orders last five years and may be withdrawn, for example if there is “a significant increase in youth uptake” (FDA, June 30, 2026).

Now the caveat both announcements carry. The January 2025 release says authorization “does not mean these tobacco products are safe, nor are they ‘FDA approved.’” The 2026 release repeats that “there is no safe tobacco product” and that “for adults who currently smoke cigarettes, fully quitting the use of all forms of tobacco products would most benefit their health.” The claim compares Zyn with cigarettes. It does not say Zyn is harmless, and it does not say it is better than quitting.

Legal status in the US and the EU

In the United States, Zyn’s 20 products have an FDA marketing authorization (January 2025) and, since June 30, 2026, modified risk orders. The FDA’s January release says the authorization lets these products be “legally marketed in the U.S. to adults 21 and older” and that the authorization is specific to those products only, not other pouches or other Zyn products. As of June 30, 2026, the FDA said it had authorized 26 nicotine pouch products in total.

In the European Union the position on snus is stricter. Article 17 of the Tobacco Products Directive 2014/40/EU says: “Member States shall prohibit the placing on the market of tobacco for oral use, without prejudice to Article 151 of the Act of Accession of Austria, Finland and Sweden” (Directive 2014/40/EU on EUR-Lex). In plain terms, the Directive requires member states to ban the sale of tobacco for oral use, with an exception clause tied to Article 151 of the Act of Accession. We did not read that article, so we do not describe what it allows, and we did not check how any country applies the ban to snus.

We did not verify the UK, Australian or any individual EU country’s rules for nicotine pouches, and we did not read the Directive’s treatment of them. If you live outside the US, check your national health authority before assuming a product is legal where you are. The youth picture is separate again: the FDA’s 2025 release cites the 2024 National Youth Tobacco Survey, in which 1.8% of US middle and high school students reported currently using nicotine pouches.

What Mayo Clinic says about tobacco substitutes

If you are weighing a switch because one of these products feels like a lesser evil, this short Mayo Clinic video makes the case against that thinking.

The video is a general warning about tobacco products and is not specific to snus or Zyn.

Which is harder to quit?

We do not have a head-to-head study, and we will not invent one. What the sources do establish is that both deliver nicotine and that nicotine is addictive. The NCI says “all tobacco products, including smokeless tobacco, contain nicotine, which is addictive.” For Zyn, the FDA has said it will monitor youth use closely, though the agency did not rank Zyn against snus on dependence.

In practice, what makes either hard to quit is the same set of things: a pouch held in the mouth through the day, linked to work breaks, driving and screens, and a cue for each one. Those cues are why a taper plan works better than willpower alone. If you use pouches, see our pouch taper plan. For the numbers on how common pouch use is, see Zyn and pouch statistics.

How to get off either one

The FDA’s position, repeated in both releases, is that “there is no safe tobacco product.” The practical plan is to reduce steadily rather than switch between products. If you use snus, our guide to quitting snus step by step sets out a plan. If you use pouches and are worried about the spend, see what Zyn costs per year.

• Count your daily pouches for a week so the baseline is real.
• Cut one pouch at the time you least need it, then hold that level for several days.
• Write down the cue for each pouch you keep: coffee, commute, a break at work.
• Plan a replacement for the hands and mouth, and a breathing exercise for the craving itself.
• Ask a pharmacist or doctor about approved quit products if cravings are strong.

iQuit supports gradual reduction as one of its quit methods, with a dashboard that tracks days nicotine-free and money saved, a craving log for triggers and intensity, SOS tools such as breathing exercises and craving surfing, and daily missions you can use in place of your pouch routines. Our guide to an app to track your quit from pouches walks through that use.

Frequently Asked Questions